[go: up one dir, main page]

AR120809A1 - Tratamiento de colitis ulcerosa con inhibidores de quinasa - Google Patents

Tratamiento de colitis ulcerosa con inhibidores de quinasa

Info

Publication number
AR120809A1
AR120809A1 ARP200103540A ARP200103540A AR120809A1 AR 120809 A1 AR120809 A1 AR 120809A1 AR P200103540 A ARP200103540 A AR P200103540A AR P200103540 A ARP200103540 A AR P200103540A AR 120809 A1 AR120809 A1 AR 120809A1
Authority
AR
Argentina
Prior art keywords
ulcerative colitis
treatment
kinase inhibitors
pyrazol
cyclobutan
Prior art date
Application number
ARP200103540A
Other languages
English (en)
Inventor
Jyoti Padmini Ramakrishna
Christopher Vujic Tehlirian
Dahong Yu
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR120809A1 publication Critical patent/AR120809A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Un método para tratar colitis ulcerosa usando compuestos y análogos que inhiben determinadas quinasas, incluida la quinasa Janus (JAK), en donde dicho método comprende la etapa de administrar al sujeto que lo necesita (1r,3r)-3-(cianometil)-3-(4-(6-(1-metil-1H-pirazol-4-il)pirazolo[1,5-a]pirazin-4-il)-1H-pirazol-1-il)ciclobutan-1-carbonitrilo, o una sal de este aceptable desde el punto de vista farmacéutico.
ARP200103540A 2019-12-18 2020-12-17 Tratamiento de colitis ulcerosa con inhibidores de quinasa AR120809A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962949995P 2019-12-18 2019-12-18

Publications (1)

Publication Number Publication Date
AR120809A1 true AR120809A1 (es) 2022-03-23

Family

ID=73856215

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200103540A AR120809A1 (es) 2019-12-18 2020-12-17 Tratamiento de colitis ulcerosa con inhibidores de quinasa

Country Status (4)

Country Link
JP (1) JP2021095402A (es)
AR (1) AR120809A1 (es)
TW (1) TW202135816A (es)
WO (1) WO2021124095A1 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20180372A (es) * 2016-02-24 2018-09-19 Pfizer Derivados de pirazolo [1,5-a] pirazin-4-ilo
US11254668B2 (en) * 2017-08-14 2022-02-22 Pfizer Inc. Pyrazolo[1,5-A]pyrazin-4-yl and related derivatives

Also Published As

Publication number Publication date
WO2021124095A1 (en) 2021-06-24
TW202135816A (zh) 2021-10-01
JP2021095402A (ja) 2021-06-24

Similar Documents

Publication Publication Date Title
MX2020010322A (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak).
CR20210098A (es) COMPUESTOS DE PIRAZOLO[3,4-b]PIRIDINA COMO INHIBIDORES DE CINASAS TAM Y MET
NZ744349A (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
MX2023002325A (es) Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
MX376856B (es) Formas de dosificacion de liberacion prolongada para un inhibidor de jak 1 (cinasa de janus 1).
MX2018012165A (es) Metodos de tratamiento de canceres pediatricos.
WO2019169065A3 (en) Wee1 kinase inhibitors and methods of treating cancer using the same
EA202191903A1 (ru) Антипролиферативные соединения и вторые активные агенты для комбинированного применения
PE20201146A1 (es) Derivado de oxi-fluoropiperidina como inhibidor de quinasa
MX2022003130A (es) Derivado de hidrazina ciclica sustituida con ciano y aplicacion del mismo.
AR119942A1 (es) Tratamiento de hidradenitis con inhibidores de quinasa
AR120799A1 (es) 2-[4-cloro-6-[2-[4-[[4-(hidroximetil)-1-piperidil]metil]fenil]etinil]-1-oxoisoindolin-2-il]-2-(6,7-dihidro-5h-pirrolo[1,2-c]imidazol-1-il)-n-tiazol-2-il-acetamida como inhibidor de egfr
AR120809A1 (es) Tratamiento de colitis ulcerosa con inhibidores de quinasa
MX2020010556A (es) Inhibidores de cinasa de insercion proviral en linfomas murinos (pim) para el tratamiento de neoplasias mieloproliferativas y fibrosis asociadas con cancer.
MX2019004602A (es) Agentes anti-proliferativos para tratar pah.
MX2022003707A (es) Compuestos de pirazolopiridina como inhibidores selectivos de quinasa btk.
PH12021551951A1 (en) Combination therapies for use in treating cancer
WO2023183936A3 (en) Combination therapy of a pi3k inhibitor and kras inhibitor and methods of use thereof
MX2024003134A (es) Metodos de tratamiento del cancer utilizando una combinacion de inhibidores de btk e inhibidores de pi3 quinasa.
AR131603A1 (es) Uso del compuesto 1 en el tratamiento o prevención de la fibrosis renal y otras enfermedades
MX2025004895A (es) Metodos para el tratamiento de la nefropatia membranosa primaria
EA202190393A1 (ru) СОЕДИНЕНИЯ ПИРАЗОЛО[3,4-b]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ TAM- И Met-КИНАЗ
NZ765152A (en) Amino-methyl piperidine derivative as kinase inhibitor
BR112023017452A2 (pt) Métodos para tratamento de vitiligo
NZ765152B2 (en) Amino-methyl piperidine derivative as kinase inhibitor

Legal Events

Date Code Title Description
FA Abandonment or withdrawal